Astellas Pharma’s Vyloy Approved by NMPA for CLDN18.2 Positive Gastric Cancer
China’s National Medical Products Administration (NMPA) has indicated on its website that Japan-based Astellas Pharma...
Drug
Sichuan Kelun-Biotech’s Ketailai Receives NMPA Approval for Nasopharyngeal Carcinoma Treatment
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that it has received marketing...
HutchMed’s Orpathys Receives Priority Review for NSCLC Treatment in China
HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) has announced that the China National Medical Products...
Zhaoke Ophthalmology’s TAB014 Achieves Positive Phase III Results for wAMD
China-based Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has...
Alphamab Oncology’s JSKN033 Advances to Phase III Trial for Platinum Resistant Ovarian Cancer
China-based Alphamab Oncology (HKG: 9966) has announced that it has received approval from the Center...
Frontera Therapeutics Advances to Phase II with FT-003 for Diabetic Macular Edema
Sino-US firm Frontera Therapeutics, Inc. has announced that it has received approval from the US...
Johnson & Johnson’s Rybrevant Combo Approved by EC for First-Line NSCLC Treatment
US healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that the European Commission...
Novartis Announces Positive Results from Phase III STEER Study on SMA Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive topline results from the Phase III...
10th National VBP Round Results Announced: Contracts Worth Over RMB1.3 Billion
The national Volume-Based Procurement (VBP) authorities have released comprehensive details regarding the 10th VBP round,...
Jiangxi Jemincare Group Gets NMPA Approval for Prostate Cancer Drug JMX-2006
China-based Jiangxi Jemincare Group has announced that it has received clinical trial approval from the...
CARsgen Therapeutics Initiates Trial for Universal CAR-T Therapy KJ-C2219 in China
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the initiation of an investigator-initiated-trial (ITT)...
Hinova Pharmaceuticals’ HP568 Earns FDA Clinical Trial Approval for ER+/HER2- Breast Cancer
Chengdu-based biotech Hinova Pharmaceuticals Inc., (SHA: 688302) has announced that it has received clinical trial...
CanSino Biologics’ Menhycia Receives Market Approval in Indonesia
China-based CanSino Biologics (HKG: 6185) has received market approval from the Badan Pengawas Obat dan...
CSPC Pharmaceutical Group Receives NMPA Approval for SYH9016 Clinical Study in Solid Tumors
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
MicuRx Pharmaceuticals’ MRX-5 Receives FDA Orphan Drug Designation for NTM Infections
Sino-US firm MicuRx Pharmaceuticals Inc. has announced that the US Food and Drug Administration (FDA)...
CARsgen Therapeutics’ Satricabtagene Autoleucel Shows Positive Results in Phase II Study
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced positive results from its pivotal Phase...
argenx’s Vygart Hytrulo Approved in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
Holland-based argenx SE (NASDAQ: ARGX) has announced receiving another indication approval from Japan’s Ministry of...
Daiichi Sankyo’s Datroway Approved in Japan for HR+, HER2- Breast Cancer
Japan-based pharmaceutical company Daiichi Sankyo (TYO: 4568) has announced that it has received marketing approval...
MabPharm’s CMAB807 Biosimilar Receives Market Approval in Indonesia and Peru
Taizhou-based MabPharm Ltd (HKG: 2181), a specialist in monoclonal antibody (mAb) biosimilars, has announced the...
BeiGene’s Tevimbra Receives FDA Approval for HER2-Negative Gastric Cancer Treatment
China-based biopharmaceutical company BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that the...